A route to new cancer therapies: the FA pathway is essential in BRCA1- or BRCA2-deficient cells

Christophe Lachaud, John Rouse (Lead / Corresponding author)

Research output: Contribution to journalArticle

1 Citation (Scopus)
230 Downloads (Pure)

Abstract

Mutations in the BRCA1 and BRCA2 genes strongly predispose carriers to breast and ovarian cancers. Two new studies reveal that FANCD2, a key component of the Fanconi anemia pathway, is essential for the survival of cells with BRCA1 or BRCA2 mutations. These findings pave the way for new 'synthetic lethal' strategies to kill BRCA-mutated cancers.

Original languageEnglish
Pages (from-to)701-703
Number of pages3
JournalNature Structural & Molecular Biology
Volume23
Issue number8
DOIs
Publication statusPublished - 3 Aug 2016

Keywords

  • Cancer
  • DNA damage and repair
  • Tumour-suppressor proteinis

Fingerprint Dive into the research topics of 'A route to new cancer therapies: the FA pathway is essential in BRCA1- or BRCA2-deficient cells'. Together they form a unique fingerprint.

  • Cite this